Onco Wiki / Rote Flagge

Homologes Rekombinationsmangel (HRD)-positives hochgradiges seröses Ovarialkarzinom (B...

Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.

IDRF-OVARIAN-HRD-POSITIVE-ACTIONABLE
ArtWarnhinweis
Statusreviewed 2026-04-27 | pending_clinical_signoff
ErkrankungenDIS-OVARIAN
QuellenSRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 SRC-NOVA-MIRZA-2016 SRC-PRIMA-GONZALEZ-MARTIN-2019

Ursprung der Roten Flagge

BegriffsbestimmungHomologous Recombination Deficiency (HRD)-positive high-grade serous ovarian carcinoma (BRCA1/2 mutation OR Genomic Instability Score ≥42). PARPi maintenance after platinum-based induction is treatment-defining: niraparib (PRIMA — mPFS 21.9 vs 10.4 mo HRD-pos), olaparib + bevacizumab (PAOLA-1 — mPFS 37.2 vs 17.7 mo HRD-pos).
Klinische RichtungIntensivierung
Kategoriehigh-risk-biology
Schaltet AlgorithmusALGO-OVARIAN-ADVANCED-1L, ALGO-OVARIAN-2L

Logik auslösen

{
  "any_of": [
    {
      "finding": "hrd_status",
      "value": "HRD-positive"
    },
    {
      "finding": "hrd_status",
      "value": "positive"
    },
    {
      "comparator": ">=",
      "finding": "genomic_instability_score",
      "threshold": 42
    }
  ],
  "type": "biomarker"
}

Anmerkungen

HRD assays: Myriad myChoice CDx (companion for olaparib + bev, niraparib), FoundationOne CDx HRD. GIS captures BRCAness (LOH + TAI + LST signatures) in tumors WT for BRCA1/2. HRD-negative HGSC has minimal PARPi maintenance benefit (PRIMA mPFS 8.1 vs 5.4 mo) — bev maintenance preferred. Coexists with RF-OVARIAN-BRCA-MUT-ACTIONABLE (BRCA-mut subset is HRD-positive by definition); RF-OVARIAN-HRD-ACTIONABILITY is the older composite version.

Verwendet von

Algorithmen

Kapitel des Handbuchs

Handbuchfragen